Greenwich LifeSciences/GLSI

$13.17

-0.15%
-
1D1W1MYTD1YMAX

About Greenwich LifeSciences

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.

Ticker

GLSI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Snehal Patel

Employees

3

Headquarters

Stafford, United States

GLSI Metrics

BasicAdvanced
$173M
Market cap
-
P/E ratio
-$0.72
EPS
3.31
Beta
-
Dividend rate
$173M
3.3093
$21.44
$7.58
43K
14.132
-106.03%
-109.97%
-109.97%
33.691
33.729
-14.48%

What the Analysts think about GLSI

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
173.35% upside
High $36.00
Low $36.00
$13.17
Current price
$36.00
Average price target

GLSI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$2.4M
-11.11%
Profit margin
0%
NaN%

GLSI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.13
-
-$0.21
-$0.19
-
Expected
-$0.23
-$0.22
-$0.20
-$0.20
-$0.20
Surprise
-43.48%
-
5%
-5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Greenwich LifeSciences stock?

Greenwich LifeSciences (GLSI) has a market cap of $173M as of May 29, 2024.

What is the P/E ratio for Greenwich LifeSciences stock?

The price to earnings (P/E) ratio for Greenwich LifeSciences (GLSI) stock is 0 as of May 29, 2024.

Does Greenwich LifeSciences stock pay dividends?

No, Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next Greenwich LifeSciences dividend payment date?

Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders.

What is the beta indicator for Greenwich LifeSciences?

Greenwich LifeSciences (GLSI) has a beta rating of 3.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Greenwich LifeSciences stock price target?

The target price for Greenwich LifeSciences (GLSI) stock is $36, which is 173.35% above the current price of $13.17. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Greenwich LifeSciences stock

Buy or sell Greenwich LifeSciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing